Table 3.
Participant demographics, treatment variables, and metabolic monitoring, stratified by age group.
| Variable | Children 4 to 12, n = 99 (%) | Adolescents 13 to 18, n = 195 (%) | χ2(1, 294) or t-value (292) | P value |
|---|---|---|---|---|
| Sex | ||||
| Female (%) | 25 (25.3) | 101 (51.8) | 18.89 | <0.001** |
| Duration of contact with clinic | ||||
| 0-1 month (%) | 22 (22.2) | 55 (28.2) | ||
| 1-3 months (%) | 6 (6.1) | 22 (11.3) | 4.06 | 0.255 |
| 3-6 months (%) | 9 (9.1) | 15 (7.7) | ||
| >6 months (%) | 62 (62.6) | 103 (52.8) | ||
| Emergency room visit | ||||
| Yes (%) | 32 (32.3) | 81 (41.5) | 2.36 | 0.125 |
| Hospital admission | ||||
| Yes (%) | 16 (16.2) | 51 (26.2) | 3.73 | 0.054 |
| Attention-deficit hyperactivity disorder diagnosis | ||||
| Yes (%) | 86 (86.7) | 101 (51.8) | 34.89 | <0.001** |
| Autism diagnosis | ||||
| Yes (%) | 12 (12.1) | 13 (4.4) | 2.51 | 0.113 |
| Anxiety diagnosis | ||||
| Yes (%) | 10 (10.1) | 43 (22.1) | 6.35 | 0.012* |
| Depression diagnosis | ||||
| Yes (%) | 0 (0.0) | 23 (11.8) | 2.67 | <0.001** |
| Second-generation antipsychotic (SGA) naïve at baseline | ||||
| Yes (%) | 49 (49.5) | 122 (62.6) | 4.61 | 0.032* |
| SGA type | ||||
| Risperidone (%) | 66 (66.7) | 66 (38.8) | ||
| Quetiapine (%) | 10 (10.1) | 78 (40.0) | 35.97 | <0.001** |
| Aripiprazole (%) | 16 (16.2) | 39 (25.0) | ||
| Olanzapine (%) | 7 (7.1) | 12 (6.2) | ||
| Other medication usea | ||||
| Yes (%) | 79 (79.8) | 156 (80.0) | 0.002 | 0.967 |
| Number of psychiatry visits | ||||
| Mean (SD) | 5.15 (3.1) | 5.67 (4.9) | –0.96b | 0.338 |
| Any baseline monitoring | ||||
| Yes (%) | 25 (25.3) | 44 (22.6) | 0.26 | 0.607 |
| Any follow-up monitoring | ||||
| Yes (%) | 24 (24.2) | 43 (22.1) | 0.18 | 0.672 |
| Weight baseline | ||||
| Yes (%) | 17 (17.1) | 28 (14.4) | 0.40 | 0.527 |
| Height baseline | ||||
| Yes (%) | 13 (13.1) | 19 (9.7) | 0.78 | 0.777 |
| Blood pressure baseline | ||||
| Yes (%) | 11 (11.1) | 19 (9.7) | 0.13 | 0.714 |
| Glucose baseline | ||||
| Yes (%) | 14 (14.1) | 21 (10.8) | 0.71 | 0.399 |
| Cholesterol baseline | ||||
| Yes (%) | 13 (13.1) | 21 (10.8) | 0.36 | 0.549 |
| Triglycerides baseline | ||||
| Yes (%) | 14 (14.1) | 21 (10.8) | 0.71 | 0.399 |
| Prolactin baseline | ||||
| Yes (%) | 11 (11.8) | 20 (10.3) | 0.05 | 0.822 |
aIn addition to SGA.
bt value for sole continuous variable of number of psychiatry visits.
*Statistically significant at P ≤ 0.05.
**Statistically significant at P ≤ 0.001.